Trevi Therapeutics
TRVI
184 hedge funds and large institutions have $1.63B invested in Trevi Therapeutics in 2025 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 75 increasing their positions, 48 reducing their positions, and 14 closing their positions.
143% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 14
56% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 48
50% more funds holding in top 10
Funds holding in top 10: 6 → 9 (+3)
38% more capital invested
Capital invested by funds: $1.18B → $1.63B (+$449M)
12% more funds holding
Funds holding: 164 → 184 (+20)
4.55% less ownership
Funds ownership: 106.2% → 101.65% (-4.6%)
29% less call options, than puts
Call options by funds: $5.3M | Put options by funds: $7.45M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$37M |
| 2 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
+$21.9M |
| 3 |
Pictet Asset Management
Carouge,
Switzerland
|
+$17.6M |
| 4 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
+$14.7M |
| 5 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$14.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$55.1M |
| 2 |
Morgan Stanley
New York
|
-$37.6M |
| 3 |
Viking Global Investors
Stamford,
Connecticut
|
-$22.3M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
-$14M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$8.96M |
TRVI Hedge Fund Activity: Q4 2025 in Review
184 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in Trevi Therapeutics (TRVI) for Q4 2025, worth a combined $1.63B — up 38% from $1.18B a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new TRVI positions and 14 closed out — a net gain of 20 holders — while 75 added to existing stakes and 48 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $37M. The largest seller was Rubric Capital Management (New York), cutting an estimated $55.1M.
- 184 institutional investors held Trevi Therapeutics (TRVI) as of Q4 2025, up from 164 in Q3 2025.
- Funds reported $1.63B of Trevi Therapeutics stock for Q4 2025, up 38% quarter-over-quarter.
- 34 funds opened new Trevi Therapeutics positions in Q4 2025 and 14 closed out, a net change of +20 holders.
- The largest Trevi Therapeutics buyer in Q4 2025 was Fidelity Investments, an estimated $37M added.
- The largest Trevi Therapeutics seller in Q4 2025 was Rubric Capital Management (New York), an estimated $55.1M sold.
Based on aggregated 13F filings for Q4 2025.